Literature DB >> 1475044

The effect of peripheral loading with kynurenine and probenecid on extracellular striatal kynurenic acid concentrations.

J M Miller1, U MacGarvey, M F Beal.   

Abstract

Kynurenic acid (KYA) is the only known endogenous excitatory amino acid antagonist in mammalian brain. In the present study we examined the effects of precursor loading with kynurenine (KYN) and blockade of organic acid transport with probenecid, either alone or in combination, on extracellular striatal KYA concentrations in unanesthetized rats. Baseline KYA concentrations were 1.61 +/- 0.29 pmol/ml. Following administration of KYN 150 mg/kg with increasing doses of probenecid a maximal increase in KYA to 946 +/- 210 pmol/ml was seen with probenecid 200 mg/kg. Probenecid 200 mg/kg alone increased KYA levels to 16.0 +/- 5.2 pmol/ml. The combination of probenecid 200 mg/kg with KYN 450 mg/kg produced a maximal increase of KYA to 2085 +/- 391 pmol/ml, a 1300-fold increase indicating marked potentiation. These results show that pharmacologic manipulation can markedly increase extracellular fluid concentrations of KYA into a range which may be useful in attempts to block NMDA receptor-mediated neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1475044     DOI: 10.1016/0304-3940(92)90186-b

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  10 in total

1.  Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model.

Authors:  E Knyihár-Csillik; J Toldi; A Mihály; B Krisztin-Péva; Z Chadaide; H Németh; R Fenyo; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2006-08-10       Impact factor: 3.575

2.  Changes in extracellular acid-base homeostasis in cerebral ischemia.

Authors:  D L Taylor; T P Obrenovitch; L Symon
Journal:  Neurochem Res       Date:  1996-09       Impact factor: 3.996

3.  Central administration of lipopolysaccharide induces depressive-like behavior in vivo and activates brain indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures.

Authors:  Xin Fu; Samantha M Zunich; Jason C O'Connor; Annemieke Kavelaars; Robert Dantzer; Keith W Kelley
Journal:  J Neuroinflammation       Date:  2010-08-02       Impact factor: 8.322

4.  Changes in extracellular kynurenic acid concentrations in rat prefrontal cortex after D-kynurenine infusion: an in vivo microdialysis study.

Authors:  Tadahiro Ogaya; Ziyu Song; Kana Ishii; Takeshi Fukushima
Journal:  Neurochem Res       Date:  2009-11-26       Impact factor: 3.996

Review 5.  The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders.

Authors:  Trevor W Stone; L Gail Darlington
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

Review 6.  Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson's disease.

Authors:  Dénes Zádori; Levente Szalárdy; József Toldi; Ferenc Fülöp; Péter Klivényi; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2012-11-30       Impact factor: 3.575

Review 7.  The spinal actions of nonsteroidal anti-inflammatory drugs and the dissociation between their anti-inflammatory and analgesic effects.

Authors:  K McCormack
Journal:  Drugs       Date:  1994       Impact factor: 9.546

8.  Transport of Kynurenic Acid by Rat Organic Anion Transporters rOAT1 and rOAT3: Species Difference between Human and Rat in OAT1.

Authors:  Yuichi Uwai; Hiroaki Hara; Kikuo Iwamoto
Journal:  Int J Tryptophan Res       Date:  2013-02-17

9.  Altered hippocampal plasticity by prenatal kynurenine administration, kynurenine-3-monoxygenase (KMO) deletion or galantamine.

Authors:  C M Forrest; K McNair; M Pisar; O S Khalil; L G Darlington; T W Stone
Journal:  Neuroscience       Date:  2015-09-10       Impact factor: 3.590

10.  Quinolinate as a Marker for Kynurenine Metabolite Formation and the Unresolved Question of NAD+ Synthesis During Inflammation and Infection.

Authors:  John R Moffett; Peethambaran Arun; Narayanan Puthillathu; Ranjini Vengilote; John A Ives; Abdulla A-B Badawy; Aryan M Namboodiri
Journal:  Front Immunol       Date:  2020-02-21       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.